Launches Let Hikma Cope With Competition On US Injectables
A stream of launches, including of vancomycin as its 100th injectable medicine in the US, is helping Hikma’s Injectables business segment to more than offset the effects of increased competition.
You may also be interested in...
Helping to alleviate shortages of critical US injectables, including controlled substances, has strengthened Hikma’s relationships with its hospital customers in the US, including with Civica Rx, CEO Siggi Olafsson told Generics Bulletin.
With local competitors in the MENA region increasingly able to compete on branded generics, Jordan’s Hikma is shifting the focus of its local operation towards partnering for patent-protected products.
The challenges of developing a US generic of GlaxoSmithKline’s Advair Diskus fluticasone/salmeterol asthma blockbuster are thinning the field and improving the commercial prospects for those that succeed, Hikma believes.